



Aligning Patient and Clinician Goals to Improve the Care of Ovarian Cancer

Clinical Brief #1 – 1L PARPi Maintenance Therapy

References

Tweet 2 References:

DiSilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance olaparib at a 7-year follow-up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: The SOLO1/GOG 3004 trial. *J Clin Oncol*. 2023;41(3):609-617. doi:10.1200/JCO.22.01549

Gonzalez-Martin A, Pothuri B, Vergote I, et al. Progression-free survival and safety at 3.5 years of follow-up: results from the randomised phase 3 PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib maintenance treatment in patients with newly diagnosed ovarian cancer. *Eur J Cancer*. 2023;189:112908. doi:10.1016/j.ejca.2023.04.024

Monk BJ, Parkinson C, Lim MC, et al. A randomized, phase III trial to evaluate rucaparib monotherapy as maintenance treatment in patients with newly diagnosed ovarian cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). *J Clin Oncol*. 2022;40(34):3952-3964. doi:10.1200/JCO.22.01003

Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. *Ann Oncol*. 2023;34(8):681-692. doi:10.1016/j.annonc.2023.05.005

Ray-Coquard I, Pautier P, Pignata S, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. *N Engl J Med*. 2019;381(25):2416-2428. doi:10.1056/NEJMoa1911361

Additional References:

Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2017;390(10106):1949-1961. doi:10.1016/S0140-6736(17)32440-6

Coleman RL, Oza A, Lorusso D, et al. O003/#557 Overall survival results from ARIEL3: a phase 3 randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. *Int J Gynecol Cancer*. 2022;32(Suppl 3):A3-A4. doi:10.1136/ijgc-2022-igcs.5

LYNPARZA® (olaparib) [prescribing information]. AstraZeneca. Approved 2014. Revised May 2023. <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208558>

Matulonis U, Herrstedt J, Oza A, et al. Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer. *Gynecologic Oncology*. 2021;162:S24-S25. doi:10.1016/s0090-8258(21)00693-4

Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. *N Engl J Med*. 2016;375(22):2154-2164. doi:10.1056/NEJMoa1611310



Poveda A, Floquet A, Ledermann JA, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2021;22(5):620-631. doi:10.1016/S1470-2045(21)00073-5

Poveda A, Lheureux S, Colombo N, et al. Olaparib maintenance monotherapy in platinum-sensitive relapsed ovarian cancer patients without a germline BRCA1/BRCA2 mutation: OPINION primary analysis. *Gynecol Oncol*. 2022;164(3):498-504. doi:10.1016/j.ygyno.2021.12.025

RUBRACA® (rucaparib) [prescribing information]. Clovis Oncology, Inc. Approved 2016. Revised December 2022.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209115>

Tew WP, Lacchetti C, Kohn EC, Panel PlitMoOCGE. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO Guideline rapid recommendation update. *J Clin Oncol*. 2022;40(33):3878-3881. doi:10.1200/JCO.22.01934

ZEJULA (niraparib) [prescribing information]. GlaxoSmithKline. Approved 2017. Revised April 2023.

<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208447>

Glossary

1L, first line
a, advanced
AE, adverse event
ALT/AST, alanine aminotransferase/aspartate aminotransferase
BID, twice daily
CR, complete response
CrCl, creatinine clearance
g, germline
Hgb, hemoglobin
HR, hazard ratio
HRd, homologous recombination deficient
HRp, homologous recombination proficient
i, inhibitor
LOT, line of therapy
m, mutant
ND, newly diagnosed
NED, no evidence of disease
NR, not reported
OC, ovarian cancer
OD, once daily
OS, overall survival
PFS, progression-free survival



Plt, platelets
PR, partial response
s, somatic
t, tumor
w/, with
wt, wild type
yo, year old